MBIO stock forecast
Our latest prediction for Mustang Bio, Inc.'s stock price was made on the May 21, 2020 when the stock price was at 3.12$.
In the short term (2weeks), MBIO's stock price should outperform the market by 5.02%. During that period the price should oscillate between -9.62% and +18.72%.
In the medium term (3months), MBIO's stock price should underperform the market by -4.98%. During that period the price should oscillate between -40.02% and +40.49%.Get email alerts
Create a solid portfolio with MBIO
About Mustang Bio, Inc.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.23$ per share.
The book value per share is 1.65$
Three months stock forecastMay 21, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|